Cocrystal Development Pipeline
Our development programs include a wide variety of serious and/or chronic viral diseases including influenza, COVID-19, gastroenteritis caused by norovirus, respiratory viruses, and hepatitis C.
| Program | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|---|
| Norovirus | Oral Pan-viral protease Inhibitor CDI-988 |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
Phase 1 complete
Phase 1b to begin in H1 2026 |
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Phase 1 complete
Phase 1b to begin in H1 2026 |
| Coronavirus | Oral Pan-viral protease Inhibitor CDI-988 |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
Phase 1 complete
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Phase 1 complete
|
| Rhinovirus | Pan-viral protease inhibitor |
Discovery Phase complete
|
Preclinical Phase in progress
Lead discovery ongoing
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Lead discovery ongoing
|
| Influenza A | Oral PB2 inhibitor CC-42344 |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
Phase 2a challenge study complete
|
Phase 3 Phase not started
|
Phase 2a challenge study complete
|
| Influenza A | Inhaled PB2 inhibitor CC-42344 |
Discovery Phase complete
|
Preclinical Phase complete
GLP tax study complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase complete
|
GLP tax study complete
|
| Influenza A & B | Oral replication inhibitor |
Discovery Phase complete
|
Preclinical Phase in progress
Lead discovery ongoing NIH SBIR Funded
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Lead discovery ongoing NIH SBIR Funded
|